Abstract: The present invention relates to an extract of Bertholletia excelsa seeds obtained from extracting an at least partly deoiled press residue of Bertholletia excelsa seeds and to a method for preparing such extract. Furthermore, the present invention refers to a cosmetic or pharmaceutic composition comprising such extract as active ingredient and to the use of the extract or the composition for skin care.

Abstract: Imidazoles of the formula ##STR1## and their non-toxic, pharmaceutically acceptable salts with acids and bases having an antagonistic activity against angiotensin II receptors.

Abstract: Imidazoles of the formula ##STR1## and their non-toxic, pharmaceutically acceptable salts with acids and bases having an antagonistic activity against angiotensin II receptors.

Abstract: Novel imidazoles of the formula ##STR1## and their non-toxic, pharmaceutically acceptable salts with acids and bases having an antagonistic activity against angiotensin II receptors.

Abstract: Novel all possible enantiomeric and diastereoisomeric forms of compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy of 1 to 5 carbon atoms, --No.sub.2, --NH.sub.2 and mono and dialkylamino of 1 to 5 alkyl carbon atoms, A and B have the trans configuration, one of A and B being ##STR2## R.sub.2 is hydrogen or alkyl of 1 to 5 carbon atoms, Z is --(CH.sub.2).sub.n2, n.sub.2 being an integer from 0 to 5 or branched alkylene of 2 to 8 carbon atoms or --CH.sub.2 --O--, Y is selected from the group consisting of phenyl, naphthyl, indenyl, heteromonocycle of 5 to 6 ring atoms and heterobicycle, all optionally having at least one substituent and the other of A and B is ##STR3## R.sub.4 and R.sub.

Abstract: Novel enantiomeric and diasteroisomeric forms of tetrahydropyridines of the formula ##STR1## wherein n.sub.1 is 0 or 2, A is selected from the group consisting of --(CH.sub.2).sub.n2 -- and alkylene substituted with alkyl having a total of 2 to 8 carbon atoms and n.sub.2 is 0 to 5, Z is selected from the group consisting of phenyl, naphthyl, indenyl, heteromonocycle of 5 to 6 ring members and heterobicycle, each optionally substituted with at least one substituent and their non-toxic, pharmaceutically acceptable acid addition salts and quarternary ammonium salts having central analgesic properties as well as diuretic, anti-arrhythmic, anti-cerebral-ischemia and hypotensive properties.

Abstract: Novel all possible enantiomeric and diastereoisomeric forms of compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy of 1 to 5 carbon atoms, --NO.sub.2, --NH.sub.2 and mono and dialkylamino of 1 to 5 alkyl carbon atoms, n is 1 or 2, A and B have the trans configuration, one of A and B being ##STR2## R.sub.2 is hydrogen or alkyl of 1 to 5 carbon atoms, Z is --(CH.sub.2)--.sub.n2, n.sub.2 being an integer from 0 to 5 or branched alkylene of 2 to 8 carbon atoms or --CH.sub.2 --O--, Y is selected from the group consisting of phenyl, naphthyl, indenyl, heteromonocycle of 5 to 6 ring atoms and heterobicycle, all optionally having at least one substituent and the other of A and B is ##STR3## R.sub.4 and R.sub.

Abstract: A compound selected from the group consisting of all possible isomeric forms, racemic or optically active of a compound of the formula ##STR1## wherein the substituents are defined in the specification, and their non-toxic, pharmaceutically acceptable acid addition salts having antiarhythmic activity.

Abstract: Novel enantiomeric and diasteroisomeric forms of tetrahydropyridines of the formula ##STR1## wherein n.sub.1 is 0 or 2, A is selected from the group consisting of --(CH.sub.2).sub.n2 -- and alkylene substituted with alkyl having a total of 2 to 8 carbon atoms and n.sub.2 is 0 to 5, Z is selected from the group consisting of phenyl, naphthyl, indenyl, heteromonocycle of 5 to 6 ring members and heterobicycle, each optionally substituted with at least one substituent and their non-toxic, pharmaceutically acceptable acid addition salts and quaternary ammonium salts having central analgesic properties as well as diuretic, anti-arrhythmic, anti-cerebral-ischemia and hypotensive properties.

Abstract: Novel 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,l-j-k][1]-benzazepin-2-(1 H)-one derivatives of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms optionally substituted with a hydroxyl, aryl and aryloxy of 6 to 10 carbon atoms, cycloalkyl of 3 to 7 carbon atoms optionally interrupted with a heteroatom optionally substituted with alkyl of 1 to 4 carbon atoms and the wavy lines indicates that the 7-OH and 6-amino have the trans configuration and their non-toxic, pharmaceutically acceptable acid addition salts having remarkable anti-hypertensive and hypotensive activity and vasodilatatory activity and their preparation.

Abstract: Novel trans cyclohept[c,d]indolols of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms and optionally substituted aralkyl of 7 to 12 carbon atoms and R.sub.1 is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms, cycloalkylalkyl of 4 to 7 carbon atoms and optionally substituted aralkyl of 7 to 12 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts having hypotensive and antihypertensive activity and a process for their preparation.

Abstract: Novel compounds selected from the group consisting of optically active isomers and racemic mixtures of cycloheptindoles of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms and optionally substituted aralkyl of 7 to 12 carbon atoms, R.sub.1 is selected from the group consisting of hydrogen, chlorine and bromine and R.sub.2 is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms, cycloalkylalkyl of 4 to 7 carbon atoms, alkenyl and alkynyl of 3 to 7 carbon atoms and optionally substituted aralkyl of 7 to 12 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts having dopaminergic agonist and antianoxic properties and a process for their preparation and novel intermediates.

Abstract: Novel benzene-propanamines of the formula ##STR1## wherein X is selected from the group consisting of hydrogen, chlorine, fluorine and bromine, R.sub.1 is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms, R.sub.2 is alkyl of 1 to 5 carbon atoms, R.sub.3 is selected from the group consisting of hydrogen, chlorine, bromine, --CF.sub.3, methyl and methoxy when R.sub.4 is nitro and R.sub.3 is selected from the group consisting of amino and acetamido when R.sub.4 is hydrogen and their non-toxic, pharmaceutically acceptable acid addition salts having anorexigenic activity and inhibit serotonine uptake in vivo and in vitro and their preparation.

Abstract: Novel derivatives of 3-(aminoethyl)-phenols of the formula ##STR1## wherein A is a simple bond or alkylene of 1 to 6 carbon atoms and B is selected from the group consisting of aryl, diarylmethyl, cycloalkyl of 3 to 10 carbon atoms and heteroaryl with the proviso that B is not phenyl when A is ethylene and their non-toxic, pharmaceutically acceptable acid addition salts having a dopaminergic activity and their preparation.

Abstract: Novel 5H-benzocyclohepten-7-amines of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen and methyl, R.sub.2 and R.sub.3 are individually selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, amino, --CF.sub.3 and methoxy, X is selected from the group consisting of hydrogen and halogen, and their non-toxic, pharmaceutically acceptable acid addition salts having remarkable in vivo and in vitro inhibiting properties for the capture of serotonine and their preparation.

Abstract: N-phenethyl-N-propyl-3,4-dihydroxyphenethylamine and its non-toxic, pharmaceutically acceptable acid addition salts possessing dopaminergic properties.

Abstract: Novel 7-aminobenzocycloheptenes of the formula ##STR1## wherein X is selected from the group consisting of --NO.sub.2, --NH.sub.2, CH.sub.3 O-- and --OH, R.sub.1 is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms, R.sub.2 is alkyl of 1 to 5 carbon atoms and R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a saturated heterocycle of 4 to 6 ring carbon atoms optionally containing a second heteroatom in the ring and optionally substituted with an alkyl of 1 to 5 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts in optically active or racemic mixture form having antidepressant activity and a process for their preparation.

Abstract: Novel phenethylamines of the formula ##STR1## wherein X is selected from the group consisting of hydrogen, acyl of an aliphatic carboxylic acid of 2 to 6 carbon atoms and benzoyl and Y is selected from the group consisting of hydrogen and --OX and their non-toxic, pharmaceutically acceptable acid addition salts having dopaminergic stimulating activity and their preparation and novel intermediates.

Abstract: Novel 7-aminomethyl-benzocycloheptenes of the formula ##STR1## wherein X is selected from the group consisting of nitro, amino, methoxy and hydroxy, R.sub.1 is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms and R.sub.2 is alkyl of 1 to 5 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts having antidepressant activity and their preparation.

Abstract: Novel benzazepines of the formula ##STR1## wherein n is 0 or 1 and R and R.sub.1 are individually selected from the group consisting of hydrogen and methyl with the proviso that when R.sub.1 is methyl, R is also methyl and their non-toxic, pharmaceutically acceptable acid addition salts having antidepressive activity and novel intermediates and processes for the preparation of the said compounds.